study_id,year,design,effect_type,effect_point,ci_low,ci_high,n_treat,n_ctrl,risk_of_bias,doi,journal_id,outcome,population,adverse_events,duration_weeks
INFL-INF03-01,2011,randomized controlled trial,SMD,-0.1958,-0.3284,-0.0632,89,92,mixed,10.1234/infl-inf03-01,inflammation-journal-01,recovery,Adults with recovery concerns,Mild GI discomfort,10
INFL-INF03-02,2016,randomized controlled trial,SMD,-0.1904,-0.3754,-0.0054,72,76,low,10.1234/infl-inf03-02,inflammation-journal-02,recovery,Adults with recovery concerns,None reported,8
INFL-INF03-03,2021,randomized controlled trial,SMD,-0.185,-0.3525,-0.0175,85,91,some concerns,10.1234/infl-inf03-03,inflammation-journal-03,recovery,Adults with recovery concerns,Transient headache,13
